LexaGene Working To Advance LX6 Pathogen Detection Instrument
In our latest exclusive interview, Alexander Smith travels to Boston, Massachusetts to visit our client LexaGene (LXG: TSXV) at its newly leased 17,500-square-foot facility. LexaGene’s President and CEO, Dr. Jack Regan, shows us how the LX6 prototype functions by taking us through its typical pathogen detection process.
To learn more about LexaGene’s technology click here.
If you’re not already a member of our newsletter and you invest in TSX Venture stocks, what are you waiting for? Subscribe today. Only our best content will land in your inbox.